You will be provided with a reference and some statements. Please determine whether each statement is 'supported', 'unsupported', or 'unknown' with respect to the reference. Please note:
First, assess whether the reference contains any valid content. If the reference contains no valid information, such as a 'page not found' message, then all statements should be considered 'unknown'.
If the reference is valid, for a given statement: if the facts or data it contains can be found entirely or partially within the reference, it is considered 'supported' (data accepts rounding); if all facts and data in the statement cannot be found in the reference, it is considered 'unsupported'.

You should return the result in a JSON list format, where each item in the list contains the statement's index and the judgment result, for example:
[
    {
        "idx": 1,
        "result": "supported"
    },
    {
        "idx": 2,
        "result": "unsupported"
    }
]

Below are the reference and statements:
<reference>
The trial to assess chelation therapy 2 (TACT2):... : American Heart Journal



Advertisement
Ovid
®
Ovid Logo

Search Ovid
Search Ovid

Browse
Browse

Login
Login
American Heart Journal
Navbar

Menu

Current Issue
Previous Issues
Latest Articles
More menu items
Search Journal
Search Journal
Button group.
Check Access
Permissions
Share
Cite
Favorite
Trial Designs
The trial to assess chelation therapy 2 (TACT2): Rationale and design
Gervasio

A.

Lamas
Kevin

J.

Anstrom
Ana

Navas-Acien
Robin

Boineau
Hwasoon

Kim
Yves

Rosenberg
Mario

Stylianou
Teresa

L.Z.

Jones
Bonnie

R.

Joubert
Regina

M.

Santella
Esteban

Escolar
Wady

Y.

Aude
Vivian

Fonseca
Thomas

Elliott
Eldrin

F.

Lewis
Michael

E.

Farkouh
David

M.

Nathan
Ana

C.

Mon
Leigh

Gosnell
Jonathan

D.

Newman
Daniel

B.

Mark
Authors and Affiliations
American Heart Journal

252
:p
1
-
11
,
October 2022
.
|
DOI:
10.1016/j.ahj.2022.05.013
Abstract
Abstract
Background
Intravenous edetate disodium-based infusions reduced cardiovascular events in a prior clinical trial. The Trial to Assess Chelation Therapy 2 (TACT2) will replicate the initial study design.
Methods
TACT2 is an NIH-sponsored, randomized, 2x2 factorial, double masked, placebo-controlled, multicenter clinical trial testing 40 weekly infusions of a multi-component edetate disodium (disodium ethylenediamine tetra-acetic acid, or Na
2
EDTA)-based chelation solution and twice daily oral, high-dose multivitamin and mineral supplements in patients with diabetes and a prior myocardial infarction (MI). TACT2 completed enrollment of 1000 subjects in December 2020, and infusions in December 2021. Subjects are followed for 2.5 to 5 years. The primary endpoint is time to first occurrence of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. The trial has >;85% power to detect a 30% relative reduction in the primary endpoint. TACT2 also includes a Trace Metals and Biorepository Core Lab, to test whether benefits of treatment, if present, are due to chelation of lead and cadmium from patients. Design features of TACT2 were chosen to replicate selected features of the first TACT, which demonstrated a significant reduction in cardiovascular outcomes in the EDTA chelation arm compared with placebo among patients with a prior MI, with the largest effect in patients with diabetes.
Results
Results are expected in 2024.
Conclusion
TACT2 may provide definitive evidence of the benefit of edetate disodiumbased chelation on cardiovascular outcomes, as well as the clinical importance of longitudinal changes in toxic metal levels of participants.
Copyright © 2022Elsevier, Inc.
Advertisement
Related Articles
Advertisement
Readers Of this Article Also Read
Advertisement
Most Popular
Advertisement
Customer Service
Submit a Service Request
Browse the help center
Privacy policy
Open Access Policy
Legal disclaimer
Terms and Copyright
Manage Cookie Preferences
Your California Privacy Choices
Copyright © 2026 Wolters Kluwer N.V. and/or its subsidiaries or third-party licensors. All rights reserved, including those for text and data mining and artificial intelligence training. For all open access content, the relevant licensing terms apply.
</reference>

<statements>
1. Disodium EDTA binds polyvalent cations—most notably lead, cadmium, and calcium—forming stable coordination compounds that undergo renal excretion
2. In an exploratory, prespecified subgroup of 633 patients with diabetes, a 41% relative reduction in primary events was reported (HR 0.59, 95% CI [0.44, 0.79])
3. A 18% trial dropout rate, with disproportionately higher consent withdrawals in the placebo group (20% vs. 13.7%)
4. Complete absence of baseline and follow-up heavy metal biomonitoring, leaving the proposed mechanism unconfirmed
5. Trial Name: **TACT** (2013)
6. Target Cohort: Post-MI adults \(\ge 50\) years
7. Interventions Evaluated: 40 infusions \(\text{Na}_2\text{EDTA}\) vs. Placebo; \(2\times2\) oral vitamins
8. Primary Outcome Endpoint: Composite of all-cause death, MI, stroke, revascularization, angina
9. Primary Result & Hazard Ratio: **Positive (Modest):** \(\text{HR } 0.82\) (\(p=0.035\)); diabetic subgroup \(\text{HR } 0.59\)
10. While the initial TACT trial suggested a modest signal of benefit driven by revascularization endpoints in a diabetic subgroup, the prospective replication trial demonstrated that reducing blood lead levels in patients with diabetes and prior myocardial infarction yields no reduction in death, recurrent infarction, stroke, or revascularization
</statements>

Begin the assessment now. Output only the JSON list, without any conversational text or explanations.